Defunct Company
Total Trials
17
As Lead Sponsor
11
As Collaborator
6
Total Enrollment
4,905
NCT01023256
Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis
Phase: Phase 1/2
Role: Lead Sponsor
Start: Dec 31, 2009
Completion: Jun 30, 2012
NCT01421186
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
Start: Jul 31, 2011
Completion: Aug 31, 2020
NCT01517282
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Start: Jan 31, 2012
Completion: Feb 28, 2014
NCT01685008
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
Phase: Phase 2
Start: Apr 23, 2013
Completion: Apr 6, 2022
NCT01685021
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
Start: Apr 30, 2013
Completion: Mar 31, 2015
NCT02005289
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Role: Collaborator
Start: Jan 17, 2014
Completion: Dec 15, 2025
NCT02399085
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
Start: Mar 29, 2016
Completion: Apr 19, 2023
NCT02739009
First in Human of Single and Multiple Doses of MOR106
Phase: Phase 1
Start: Apr 30, 2016
Completion: Aug 1, 2017
NCT02639910
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
Start: Nov 30, 2016
Completion: Dec 31, 2021
NCT03102320
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
Start: May 26, 2017
Completion: Jul 26, 2021
NCT04150328
Lenalidomide Monotherapy in R/R DLBCL
Phase: N/A
Start: Apr 12, 2019
Completion: Aug 25, 2020
NCT04134936
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
Start: Dec 11, 2019
Completion: Aug 10, 2022
NCT04697160
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
Start: Apr 1, 2020
Completion: May 7, 2021
NCT04893096
MOR202 for Refractory MN
Start: Oct 22, 2021
Completion: Feb 21, 2025
NCT05626322
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Start: Aug 4, 2023
Completion: May 1, 2025
NCT06029309
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Start: May 3, 2024
Completion: May 1, 2032